Yuki Arakawa

987 total citations
31 papers, 201 citations indexed

About

Yuki Arakawa is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Molecular Biology. According to data from OpenAlex, Yuki Arakawa has authored 31 papers receiving a total of 201 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Hematology, 12 papers in Public Health, Environmental and Occupational Health and 7 papers in Molecular Biology. Recurrent topics in Yuki Arakawa's work include Acute Lymphoblastic Leukemia research (11 papers), Acute Myeloid Leukemia Research (7 papers) and Childhood Cancer Survivors' Quality of Life (5 papers). Yuki Arakawa is often cited by papers focused on Acute Lymphoblastic Leukemia research (11 papers), Acute Myeloid Leukemia Research (7 papers) and Childhood Cancer Survivors' Quality of Life (5 papers). Yuki Arakawa collaborates with scholars based in Japan, Italy and Singapore. Yuki Arakawa's co-authors include Katsuyoshi Koh, Ryoji Hanada, Makiko Mori, Takahiro Aoki, Hiroshi Kawashima, Hiroshi Kishimoto, Shinichiro Motohashi, Moeko Hino, Naoki Shimojo and Kentaro Watanabe and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Yuki Arakawa

23 papers receiving 198 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yuki Arakawa Japan 7 67 63 37 36 32 31 201
Shankaranarayana Paneesha United Kingdom 8 67 1.0× 58 0.9× 86 2.3× 36 1.0× 41 1.3× 21 284
Masahiro Sekimizu Japan 8 89 1.3× 44 0.7× 42 1.1× 23 0.6× 25 0.8× 42 249
Catherine Vézina Canada 7 169 2.5× 74 1.2× 51 1.4× 30 0.8× 63 2.0× 12 295
F. Pagliai Italy 8 62 0.9× 35 0.6× 68 1.8× 32 0.9× 49 1.5× 11 284
Ingrid Vášová Czechia 7 153 2.3× 78 1.2× 30 0.8× 59 1.6× 33 1.0× 35 293
Réda Garidi France 9 63 0.9× 97 1.5× 51 1.4× 93 2.6× 11 0.3× 16 261
Selmin Ataergın Türkiye 9 83 1.2× 23 0.4× 68 1.8× 24 0.7× 20 0.6× 30 238
Rabea Wagener Germany 8 37 0.6× 25 0.4× 21 0.6× 36 1.0× 24 0.8× 26 236
Catherine Burton United Kingdom 7 86 1.3× 57 0.9× 16 0.4× 39 1.1× 20 0.6× 15 210
Yasir Khan United States 9 62 0.9× 79 1.3× 20 0.5× 29 0.8× 21 0.7× 24 211

Countries citing papers authored by Yuki Arakawa

Since Specialization
Citations

This map shows the geographic impact of Yuki Arakawa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuki Arakawa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuki Arakawa more than expected).

Fields of papers citing papers by Yuki Arakawa

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuki Arakawa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuki Arakawa. The network helps show where Yuki Arakawa may publish in the future.

Co-authorship network of co-authors of Yuki Arakawa

This figure shows the co-authorship network connecting the top 25 collaborators of Yuki Arakawa. A scholar is included among the top collaborators of Yuki Arakawa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuki Arakawa. Yuki Arakawa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Arakawa, Yuki, Takahiro Ishikawa, Kohei Fukuoka, et al.. (2024). Efficacy of off-the-shelf bone marrow mesenchymal stem cells for pediatric steroid-refractory acute graft-versus-host disease. PubMed. 6(4). 1–9. 5 indexed citations
2.
Fujita, Takashi, Hiroko Fukushima, Toru Nanmoku, et al.. (2023). Acute monocytic leukemia with KMT2A::LASP1 developed 9 months after diagnosis of acute megakaryoblastic leukemia in a 2-year-old boy. International Journal of Hematology. 118(4). 514–518.
3.
4.
Arakawa, Yuki, Daisuke Hasegawa, Takako Miyamura, et al.. (2022). Postchemotherapy immune status in infants with acute lymphoblastic leukemia: A report from the JPLSG MLL‐10 trial. Pediatric Blood & Cancer. 69(10). e29772–e29772.
5.
Arakawa, Yuki, Takahiro Hosokawa, Makiko Mori, et al.. (2022). Predictive risk score of respiratory complications in children with mediastinal tumors: A case–control study. Cancer Medicine. 12(2). 1167–1176. 4 indexed citations
6.
7.
Arakawa, Yuki, Makiko Mori, Kohei Fukuoka, et al.. (2021). Successful perioperative management using prothrombin complex concentrates in patients with severe congenital protein C deficiency. Pediatric Blood & Cancer. 69(1). e29380–e29380. 3 indexed citations
8.
Arakawa, Yuki, Satoshi Masutani, Koichi Oshima, et al.. (2021). Asian population may have a lower incidence of hip osteonecrosis in childhood acute lymphoblastic leukemia. International Journal of Hematology. 114(2). 271–279. 2 indexed citations
9.
Fukuoka, Kohei, et al.. (2020). [Gilteritinib for pediatric FLT3 internal tandem duplication-positive recurrent acute myeloid leukemia].. PubMed. 61(4). 322–326. 1 indexed citations
10.
Kubota, Yasuo, Yuki Arakawa, Masahiro Sekiguchi, et al.. (2019). A case of malignant rhabdoid tumor mimicking yolk sac tumor. Pediatric Blood & Cancer. 66(8). e27784–e27784. 9 indexed citations
11.
Tanaka, Yoïchi, Motohiro Kato, Takaya Moriyama, et al.. (2018). Tolerable Dose of 6-Mercaptopurine and Prognostic Impact of NUDT15-Deficient Genotype in Childhood Acute Lymphoblastic Leukemia. Blood. 132(Supplement 1). 4032–4032. 1 indexed citations
12.
Arakawa, Yuki, et al.. (2018). Cost-effectiveness Analysis of Pegfilgrastim in Patients with Non-Hodgkin Lymphoma for the Primary Prophylaxis of Febrile Neutropenia Associated with CHOP Chemotherapy. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences). 44(9). 441–448.
13.
Amano, Hizuru, Hiroo Uchida, Yujiro Tanaka, et al.. (2017). Excellent prognosis of patients with intermediate-risk neuroblastoma and residual tumor postchemotherapy. Journal of Pediatric Surgery. 53(9). 1761–1765. 4 indexed citations
14.
Aoki, Takahiro, Moeko Hino, Katsuyoshi Koh, et al.. (2016). Low Frequency of Programmed Death Ligand 1 Expression in Pediatric Cancers. Pediatric Blood & Cancer. 63(8). 1461–1464. 68 indexed citations
15.
16.
Tanaka, Yujiro, Hiroshi Kawashima, Makiko Mori, et al.. (2016). Contraindications and image-defined risk factors in laparoscopic resection of abdominal neuroblastoma. Pediatric Surgery International. 32(9). 845–850. 20 indexed citations
17.
Kato, Motohiro, Atsushi Manabe, S Ishimaru, et al.. (2015). Long-term outcome of six months maintenance chemotherapy for ALL in children: TCCSG L92-13E study.. Journal of Clinical Oncology. 33(15_suppl). 10032–10032.
18.
Aoki, Takahiro, Katsuyoshi Koh, Yutaka Kawano, et al.. (2015). Safety of Live Attenuated High-Titer Varicella-Zoster Virus Vaccine in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients. Biology of Blood and Marrow Transplantation. 22(4). 771–775. 16 indexed citations
19.
Arakawa, Yuki, Motohiro Kato, Katsuyoshi Koh, & Ryoji Hanada. (2014). Unrelated cord blood and bone marrow transplantation in pediatric leukemia. Pediatrics International. 56(4). 647–650. 4 indexed citations
20.
Yoshino, Hiroshi, Yuki Arakawa, Takashi Nakazawa, et al.. (1990). Synthesis and biological activity of (MeTyr1,MeArg7,D-Leu8)-dynorphin A(1-9)-NHEt and (D-Cys2-Cys5,MeArg7,D-Leu8)-dynorphin A(1-9)-NH2.. Chemical and Pharmaceutical Bulletin. 38(8). 2274–2276. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shankaranarayana Paneesha Breakdown of academic impact, for papers by Masahiro Sekimizu Breakdown of academic impact, for papers by Catherine Vézina Breakdown of academic impact, for papers by F. Pagliai Breakdown of academic impact, for papers by Ingrid Vášová Breakdown of academic impact, for papers by Réda Garidi Breakdown of academic impact, for papers by Selmin Ataergın Breakdown of academic impact, for papers by Rabea Wagener Breakdown of academic impact, for papers by Catherine Burton Breakdown of academic impact, for papers by Yasir Khan
Rankless by CCL
2026